Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
PaperCitations, authors & open-access status
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 806 citations, 2019 year and closed oa status.
806
Citations
2019
Year
closed
OA Status